KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) FCF Margin (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed FCF Margin for 13 consecutive years, with 23.84% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 7160.0% year-over-year to 23.84%, compared with a TTM value of 7.67% through Dec 2025, up 10955.0%, and an annual FY2025 reading of 7.7%, up 10954.0% over the prior year.
  • FCF Margin was 23.84% for Q4 2025 at Travere Therapeutics, down from 35.44% in the prior quarter.
  • Across five years, FCF Margin topped out at 57.66% in Q3 2021 and bottomed at 327.8% in Q3 2022.
  • Average FCF Margin over 5 years is 97.06%, with a median of 58.48% recorded in 2025.
  • The sharpest move saw FCF Margin crashed -38546bps in 2022, then soared 25279bps in 2024.
  • Year by year, FCF Margin stood at 55.91% in 2021, then tumbled by -113bps to 7.43% in 2022, then crashed by -470bps to 42.3% in 2023, then fell by -13bps to 47.76% in 2024, then skyrocketed by 150bps to 23.84% in 2025.
  • Business Quant data shows FCF Margin for TVTX at 23.84% in Q4 2025, 35.44% in Q3 2025, and 4.35% in Q2 2025.